We all know that medical data is sensitive personal information, which we would not like to have falling into the wrong hands. Along with the progress of digitalisation in healthcare, the number of cyberattacks towards this particular sector has dramatically increased over the past years. The ultimate risk? Slowed or even paralysed hospitals, with lives lost as a consequence. Since all of this happens in the background, it’s hard to grasp the severity of the situation, and the majority of us are not equipped with the expertise to understand how those events actually unfold. With decades of experience as a healthcare Chief Information Security Officer and current Chief Security Strategist at Cylera, Richard Staynings has seen firsthand the devastating consequences of such attacks on patients, providers, and organizations. But he's also a firm believer that with the right strategies, tools, and mindset, we can win the war against cyber threats in healthcare. In this episode, we dive headfirst into the high-stakes world of healthcare cybersecurity with one of the industry's most respected voices. You will learn about: The risks cyberattacks carry for health systems The most common types of cyberattacks in this sector The entities behind those threats What health systems can do to ensure their safety A conversation packed with eye-opening perspectives and actionable advice for anyone working in healthcare or concerned about its future! Timeline: 02:14 - introduction on Richard’s background and the mission of Cylera 03:26 - why cybersecurity matters in healthcare 07:58 - the example of WannaCry in the UK 10:46 - the main sources of threat for healthcare systems 29:46 - the approach Cylera takes to safeguard its clients What we also talked about with Richard: General Keith Alexander Malware Ransomware Denial-of-service attack Zero-day exploits The Interview The CIA Triad As mentioned in the episode, you can learn more about Cylera through their website and their approach here. You can also follow their activities on LinkedIn or Twitter! For further information about cybersecurity in healthcare, we’d recommend the Blog section from Cylera and the website curated by Richard himself: cyberthoughts.org. If you want to get in touch with Richard, feel free to contact him per email at [email protected], on LinkedIn or Twitter. In case you want to give me feedback on the episode or the podcast in general, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at [email protected]! If you liked the episode, please share it, subscribe to the podcast and leave a 5-star review on streaming platforms! We also invite you to follow our activities through our website, LinkedIn and Instagram!

To discover the whole episode type "#19 - Saving lives through cybersecurity - Richard Staynings - Cylera" on your streaming platform.

Most of our genome does not code for any protein, which led us to believe that 98% of our genetic material was useless. But what was initially termed as the “dark side of the genome” (which Star Wars fans will certainly appreciate!) turns out to play a crucial role in modulating our biology. It is in fact the software translating environmental factors (e.g. air quality, lifestyle, stress, etc.) into biological mechanisms, which can either lead to the proper functioning of our body or to certain illnesses. The stakes and the potential around its use to develop new treatments are therefore immense! And this is exactly what HAYA Therapeutics has been focusing on over the past few years: leveraging the science behind the “dark genome” to develop revolutionary treatments for chronic diseases, starting with heart failure. The promise compared to traditional approaches? More effective and targeted effects, focusing on one type of tissue only Lower therapy development costs due to shorter development processes So what stands behind this mysterious concept exactly? What is the science behind it? And how can this drive the development of new therapies to address some of the most widespread conditions across the globe? In this new episode of Impulse, learn all about this fascinating field in the words of Samir Ounzain - CEO from HAYA Therapeutics - on a mission to radically change the way we approach drug discovery and development. Passionate and didactic, he unveils the secrets of the “dark genome”, the influence of our surrounding environment on our genetics, and how we could leverage our understanding of this field to treat chronic diseases in a new way! Timeline: 02:32 - Samir’s background and how he got passionate about genetics 08:30 - What the “dark genome” is actually about 11:38 - How our understanding of the “dark genome” sparked the idea of what will become HAYA Therapeutics 25:30 - How HAYA Therapeutics aims to address heart failure 32:47 - Longevity and other applications on the long run 36:42 - How such new treatment would be delivered What we also talked about with Samir: Jurassic Park Wisper long noncoding RNA RNA interference & Anti-Sense Oligonucleotides Renin-angiotensin system We cited with Samir some of the past episodes from the series: #1 - Measuring your arterial age to prevent heart diseases - Ted Baldwin - Imageens As mentioned in the episode, you can learn more about HAYA Therapeutics through their website and their approach here. You can also follow their activities on LinkedIn or Twitter! For further information about the dark side of the genome and the science behind it, we’d recommend you to check out the book from John Mattick and Paulo Amaral entitled “RNA the Epicenter of Genetic Information”, as well as the interview of Manolis Kelis on Lex Fridman Podcast. A recent article by the BBC featuring Samir also details out what the dark genome is about and goes quite deep into the topic, worth checking out as well! If you want to get in touch with Samir, feel free to contact him per email at [email protected], on LinkedIn or Twitter. In case you want to give me feedback on the episode or the podcast in general, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at [email protected] If you liked the episode, please share it, subscribe to the podcast and leave a 5-star review on streaming platforms! We also invite you to follow our activities through our website, LinkedIn and Instagram pages!

To discover the whole episode type "#18 - The dark genome as the next revolution in drug discovery - Samir Ounzain - HAYA Therapeutics" on your streaming platform.

How can we support each and every one of us in identifying and pursuing our goals towards a healthier life, in a world where access to care seems to be continuously shrinking? The solution may lie in health coaching and making it accessible across the globe. Having witnessed his wife successfully battling breast cancer and becoming a certified health coach, Eugene Borukhovich joined her entrepreneurial adventure at YourCoach.Health in 2020 to co-found the first and only operating system for behavior change powered by an army of helath and wellness coaches. As a recognized and beloved leader in the healthcare space, Eugene relies on his incredibly diverse experience in the space - as an intra- and entrepreneur, executive, venture builder, advisor and even podcaster - to drive the operations of the platform. Three years down the line, it regroups more than 3000 certified health coaches, impacting a number of lives higher by several orders of magnitude, on a daily basis. There is still a long way to go to reach the projected 9 billion people on earth by 2030, but their determination is unquestionable: join the journey and learn all about health coaching in this new episode, the science behind it, and what it can do for you! Timeline: 02:22 - Eugene’s background in healthcare and most particularly digital health 07:35 - What triggered Eugene’s move towards entrepreneurship and health coaching 11:19 - What health coaching is about 20:41 - Moving from a Global corporate role to being your own boss 24:54 - Eugene’s take on making collaborations between startups and corporates in healthcare successful 29:23 - What led Eugene to go into podcasting and start the DTx Podcast and Shot of Digital Health Therapy What we also talked about with Eugene: Meetup Scott Heiferman Matthew Holt Indu Subaiya Health 2.0 Conference Lark Health Twill Marina Borukhovich Bayer G4A Hard Pill To Swallow Dan Kendall Jim Joyce As mentioned in the episode, you can learn more about YourCoach.Health through their website and their app available on the App Store or Google Play Store. You can also follow their activities on LinkedIn, Instagram, Twitter and Facebook! For further information about health coaching and the science behind it, we’d recommend you to check out the podcast produced by the YourCoach.Health team, as well as The National Board for Health and Wellness Coaching. If you want to get in touch with Eugene, feel free to contact him per email at [email protected], or on LinkedIn, Twitter and Instagram. In case you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at [email protected] If you liked the episode, share it, subscribe to the podcast and leave a 5-star review on streaming platforms! We also invite you to follow our activities through our website, LinkedIn, Twitter and Instagram pages.

To discover the whole episode type "#17 - Coaching as the key to a better health - Eugene Borukhovich - YourCoach.Health" on your streaming platform.

Starting a career in the Israeli army, becoming a lawyer, and finally transforming the field of medical imaging. In a very schematic way, this is what might define Ohad Arazi’s path, who is now spearheading the field of handheld ultrasound as the CEO of Clarius. His curiosity for medical imaging - coupled with a very product-oriented mindset and an unrelenting desire to understand the problems that healthcare faces - leads him to integrate different structures, including the Fortune 500 giant McKesson, the Canadian telecommunication company Telus, and the Israeli startup Zebra Medical Vision, where he quickly occupies leadership roles with great responsibility. At Clarius (this “true gem” as he calls it in his own words) he draws on his expertise in the field of medical imaging to embed artificial intelligence into the most compact high quality ultrasound imaging platform on the market, developed by its brilliant founder Laurent Pelissier. The goal? Allowing any healthcare professional to perform an ultrasound scan, with a system as intuitive, qualitative, and compact as an iPhone. Perhaps those will even find their place in patient’s homes at some point! In light of the current boom in digital health and the radical developments in AI, Ohad shares his perspective on the role that these technologies will have on certain medical specialities and notably radiology, where he believes that they will rather augment them without replacing them. He also explains why he thinks that most technological capabilities in digital health are outstripping the value they can create, and reflects on his career path where his transitions from huge corporates to human-sized startups shaped his evolution and leadership. A surprising dive into the future of medical imaging, that we invite you to discover in this new episode! Timeline: 02:23 - Ohad’s background, from the military in Israel to healthcare in Canada 10:46 - What the medical imaging landscape looked like in the early 2000s 14:51 - Ohad’s take on the current boom in digital health 19:36 - Clarius’ mission in transforming high-end ultrasound for healthcare professionals 33:11 - How AI is embedded into the products from Clarius 35:09 - Dealing with hypergrowth as a medical imaging startup 39:48 - Ohad’s reflections on his career path and the story of the Disney brothers What we also talked about with Ohad: OpenAI Turtle Health US2.ai PACS DICOM EHR James Hare Carolyn Lam We cited with Ohad some of the past episodes from the series: #1 - Measuring your arterial age to prevent heart diseases - Ted Baldwin - Imageens #12 - Unleashing the power of digital health - Daniel Kraft - Digital.Health As mentioned in the episode, you can learn more about Clarius through their website and follow their activities on LinkedIn, Twitter, Facebook, Instagram and YouTube! If you want to get in touch with Ohad, feel free to contact him per email at [email protected] or through LinkedIn. If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at [email protected] And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! Finally, you can follow our activities through our website, over LinkedIn, Twitter or on Instagram!

To discover the whole episode type "#16 - Making ultrasound portable to transform medical imaging - Ohad Arazi - Clarius" on your streaming platform.

Nicolas Durand is the CEO of Abionic, a Swiss-based startup which developed and commercialises the abioSCOPE®, a unique diagnostic platform characterised by its compact size and ability to deliver high quality results in a fraction of time. Passionate about high tech and wishing to become an entrepreneur from a very early age (he created his first company with a friend at school when he was 14 years old) he turned his PhD work into a venture, which today represents one of the most successful medtech startups in the country! We discuss with Nicolas the nanotechnology behind Abionic, the types of tests it can run, the targeted diseases, the efforts it takes to demonstrate the clinical efficacy of a new diagnostic device, but also the energy required to convince all the actors involved in the care pathway, from regulators, doctors, to patients. He also shares openly about his vision regarding the potential emergence of home diagnostic systems in the future, as well as his perspective on the impact that the Theranos scandal had on the diagnostics industry, and in particular on startups operating in this field. A conversation under the sign of resilience and excellence that we invite you to discover in this new episode! Timeline: 01:15 - Nicolas’ background and his original interest in high technology and entrepreneurship 03:12 - Creating your first company at 14 years old 05:59 - What Abionic is about and how its core diagnostic technology works 20:50 - Miniaturizing diagnostic tests beyond immunoassays 24:12 - The clinical settings where the abioSCOPE® is placed 26:35 - Towards the use of diagnostic systems at home 31:20 - The impact of the Theranos scandal on medtech startups What we also talked about with Nicolas: Philippe Renaud Robopoly PSP Sepsis IVDR Elizabeth Holmes Red Bull Air Race We cited with Nicolas some of the past episodes from the series: #4 - Fighting sepsis with nanoengineered beads to filter the blood - Lukas Langenegger - Hemotune #5 - Transforming diagnostics through spatial biology - Déborah Heintze - Lunaphore #12 - Unleashing the power of digital health - Daniel Kraft - Digital.Health #13 - Catalyzing drug discovery using organ-on-a-chip models - Bas Trietsch - Mimetas As mentioned in the episode, you can learn more about Abionic through their website and follow their activities on LinkedIn, Twitter and Facebook! Based on Nicolas’ suggestion, we invite you to read Bad Blood: Secrets and Lies in a Silicon Valley Startup by John Carreyrou to learn more about Elizabeth Holmes and the scandal around Theranos which literally shook the whole medtech industry in the past years! If you want to get in touch with Nicolas, feel free to contact him per email at [email protected] or through LinkedIn. If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at [email protected] And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! Finally, you can follow our activities through our website, over LinkedIn, Twitter or on Instagram!

To discover the whole episode type "#15 - Propelling diagnostics through miniaturization - Nicolas Durand - Abionic" on your streaming platform.

Will the next revolution in personalized health be led by connected clothes? This is the bet that Vincent Martinez and his team at Nanoleq are making, and they are putting all their efforts into turning their vision into reality! Originally, their idea was to target the cable industry with a proprietary technology enabling to create stretchable cables, with superior physical and electrical properties. The targeted companies being too slow in their adoption of the proposed approach, Vincent and his team decide to tackle the field of connected clothing, by proposing a set of components and tools enabling any clothing manufacturer to turn their garments into smart ones, able to measure multiple vital parameters but also to electrically stimulate certain regions of the body. Building upon their expertise in this space, they developed the first breathing smart garment with live biofeedback - Oxa - around which they designed a whole personalized program for everyone to reconnect to their body through breathing, the only vital sign we can consciously control. We talked with Vincent about the emergence of connected clothes and what role they will play in the preservation of our health, how stretchable electronics work, and how Nanoleq managed to develop a full breathing experience combining cutting-edge sensors with gamification, backed by the most renown ambassadors in the field. Timeline: 00:58 - Vincent’s background at the interface of materials science and biomedical engineering 02:57 - Launching a company to address the premature breakage of electronic cables 07:45 - What lies behind the term « stretchable electronics » 09:55 - Shifting the focus towards smart textiles 19:48 - The vision of Nanoleq around connected health 24:05 - Starting a new product line focused on breathing optimization: Oxa Life 35:00 - Federating a community of breathing specialists 37:46 - Making the most personalised and digitally engaging breathing optimization program 44:14 - Towards everyday wear of smart clothes What we also talked about with Vincent: ETH Pioneer Fellowships Luca Hirt Grégoire Courtine Start Summit Venture Kick Venture Electrical Muscle Stimulation (EMS) Wim Hof Sleep apnea Dan Brulé Headspace Petit Bambou Andrew Huberman We cited with Vincent some of the past episodes from the series: #6 - Bringing back walking to paraplegics - Jocelyne Bloch - .NeuroRestore #11 - Turning the lab into a wearable platform - Esmeralda Megally - Xsensio As mentioned in the episode, you can learn more about Nanoleq and the field of stretchable electronics through their website. The Kickstarter campaign for Oxa runs until Sunday December 18 and you can contribute to it at this page! For more information about Oxa, check out the official product page: www.oxalife.com. Based on Vincent’s suggestions, check out the book Breath from James Nestor or this episode of Huberman Lab if you want to know more about the science behind breathing and the exercises that we discussed in this episode. You can also learn more about the Buteyko method here. If you want to get in touch with Vincent, feel free to contact him per email at [email protected] or through LinkedIn. If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at [email protected] And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! Finally, you can follow our activities through our website, over LinkedIn, Twitter or on Instagram!

To discover the whole episode type "#14 - Preserving our health with smart clothes - Vincent Martinez - Nanoleq" on your streaming platform.

Developing a new drug is a tough and strenuous endeavour, requiring investments that go beyond $1 billion and sometimes up to 15 years of time. On top of that, only 1 out of 10 drug candidates successfully passes clinical trial testing and regulatory approval. The Dutch company Mimetas, specialized in the use of organ-on-a-chip technology, aims to address exactly this challenge by accelerating this laborious process and making it more predictable. Their expertise actually lies in the development of in-vitro human tissue models (including diseases) which recapitulate the cellular complexity but also the biochemical and mechanical cues that make up the real tissues from our body. Such models can then be used as a powerful experimental platform for drug discovery, since they reflect our actual biology so well. Bas Triestch is one of the three founders from Mimetas (alongside Jos Joore and Paul Vulto) who saw in the early 2010s the potential to leverage organ-on-a-chip methods at scale for the benefit of drug discovery, leading them to become the most innovative Dutch company in 2022! In this episode, Bas takes us behind the scenes of the fascinating science that they are driving at Mimetas, the impact that they are having on the R&D efforts from some of the biggest players in the biotech industry, but also the shift that they have operated as a company, starting as a “hardware” provider and gradually becoming a specialized scientific service firm. Timeline: 01:35 - Bas’ background and the origins of Mimetas centered around new drug discovery approaches 05:31 - What organ-on-a-chip technology means and how it serves the development of new human tissue and disease models 09:05 - The OrganoPlate® as the key platform providing scalability and reproducibility for the study of such models 15:40 - Merging organoids and organ-on-a-chip technologies in a unique platform, the OrganoPlate® Graft 24:03 - Moving from better understanding diseases, through medication guidance, and up to personalized medicine 28:47 - Mimetas’ mission in accelerating the development of new treatments and finding the right drugs for the right patients 34:50 - Dealing with substantial amount of experimental data 39:24 - Shifting Mimetas’ business model from selling hardware components to offering specialized scientific services in the field of drug discovery What we also talked about with Bas: Leiden University Hans Clevers Roche Galapagos Trans-Epithelial Electrical Resistance (TEER) Wnt signaling pathway We cited with Bas some of the past episodes from the series: #5 - Transforming diagnostics through spatial biology - Déborah Heintze - Lunaphore #8 - Using organoids to transform drug discovery - Nikolce Gjorevski - Roche As mentioned in the episode, you can learn more about Mimetas and the field of organ-on-a-chip engineering through their website. Based on Bas’ recommendation, we also invite you to check out this review to get a deeper understanding of the field and where it stands at the moment. If you want to get in touch with Bas, feel free to contact him per email at [email protected] or through LinkedIn. If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at [email protected] And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! Finally, you can follow our activities through our website, over LinkedIn, Twitter or on Instagram!

To discover the whole episode type “#13 - Catalyzing drug discovery using organ-on-a-chip models - Bas Trietsch - Mimetas" on your streaming platform.

Daniel Kraft is a surprising and admirable figure in the digital health landscape. Originally trained as a physician in internal medicine and pediatrics, he then distinguished himself by his research work focusing on regenerative medicine, while at the same time initiating several entrepreneurial projects in the medtech space. RegenMed Systems is one of them, a company that he founded and which led him to create a new type of medical device to facilitate bone marrow harvest procedures. IntelliMedicine is another one, where he aims to create a system enabling patients to 3D print their own medication at home, avoiding the intake of multiple pills on a daily basis. Aside from his own entrepreneurial endeavours, he advises several Fortune-50 and digital health-related startups, and is on the board of Healthy.io. As one of the most renowned ambassadors of digital health, he is driven by the conviction that innovation in this space can only result from the synergies of disciplines and technologies that may initially be totally distant from the medical sphere. Through his activities at the Singularity University or through the program Exponential Medicine that he initiated, he brings together brilliant minds from a broad range of specialties who come together to explore convergent and rapidly developing technologies, to develop relevant applications in healthcare. Often called upon to speak to the future of health, medicine and technology, he has already given multiple TED and TEDMED Talks, and delivered keynotes to a wide array of organizations on those subjects. We talked with Daniel about his early days in the healthcare world, why he decided to study medicine and orient himself on this path, his perspective on the importance of collaboration and boldness when it comes to creating new digital health solutions, what the future looks like from his lens, but also how he manages to stay on top of things while keeping a healthy lifestyle! Timeline: 00:59 - Daniel’s background moving from medical studies, through biomedical research, entrepreneurship and thought leadership in digital health 03:56 - What drove Daniel to start a career in healthcare 05:54 - How converging new digital technologies can benefit medical progress 09:00 - The shift in adoption within the medical community towards digital health 10:49 - The types of medical data available these days to advance our understanding and management of diseases 14:30 - Establishing a general database to reference all things digital health - Digital.Health 20:16 - Zooming in on RegenMed Systems and IntelliMedicine 26:25 - A lookout on Daniel’s potential future projects in healthcare 31:54 - Daniel’s tips and secrets on his (almost) endless source of energy and drive What we also talked about with Daniel: Bits & Pretzels HealthTech Xolair Stanford Byers Center for Biodesign NASA IBM Watson CRISPR/Cas9 Continuum Health Ventures Digitale Gesundheitsanwendungen (DiGA) You can learn more about Daniel’s activities through his website (we recommend you to subscribe to his weekly newsletter), and you can follow him on LinkedIn and Twitter. For a deep-dive into digital health solutions, we recommend you to consult Digital.Health, the database that Daniel and his team put together and which regroups most of the solutions already available out there. In case you want to experience the thrill of digital health and share your ideas with some of the brightest minds in the field, check out NextMed.Health, the conference in San Diego curated by Daniel and his team from March 13 to 16 next year. If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: [email protected] And if you liked the episode, don’t hesitate to share it, subscribe to the podcast, leave a positive review on streaming platforms and follow our activities on LinkedIn, Instagram, Twitter as well as on our website!

To discover the whole episode type “#12 - Unleashing the power of digital health - Daniel Kraft - Digital.Health" on your streaming platform.

Miniaturizing the lab to allow for the continuous analysis of proteins and hormones circulating in our body through a wearable. This is the aim of Xsensio - a Swiss startup developing the Lab-on-Skin(c) platform - which will enable in the future to continuously track compounds present in the interstitial fluid, right underneath our skin. It is in essence a similar concept as the established continuous glucose measurement devices (which are nowadays moving from pure medical applications to consumer-oriented wellness programs), the difference being the type of biomarkers that the Lab-on-Skin(c) platform will enable to monitor - proteins and hormones on-body, continuously and in real-time - opening applications ranging from cardiology to oncology, in the hospital setting or at home. Esmeralda Megally (CEO of the company) shares with us her vision around personalized medicine and which role the Lab-on-Skin(c) platform will play in this regard. With passion, she explains us the concepts behind the functioning of this surprising technology, what it takes to bring it to the market, and reveals the potential synergies that it may have in the future with the current wearables that are already part of our daily living. Timeline: 02:20 - Esmeralda’s background and how it led to the creation of Xsensio 09:14 - The unmet need that Xsensio is addressing with its Lab-on-Skin(c) platform 13:51 - The applications where the Lab-on-Skin(c) platform will play a role 17:28 - The functioning of the Lab-on-Skin(c) platform and its components 22:50 - What lies ahead of Xsensio before making its first product commercialized 28:09 - Combining the Lab-on-Skin(c) platform with traditional wearables data 29:57 - Defining a medical product development roadmap in an emerging field and how to deal with accompanying uncertainty What we also talked about with Esmeralda: Fitbit Apple Watch Bill & Melinda Gates Foundation Lab for Youth Mental Health NANOLAB Veri Supersapiens C-reactive protein Troponin T Mayo Clinic Rea Diagnostics We cited with Esmeralda some of the past episodes from the series: #4 - Fighting sepsis with nanoengineered beads to filter the blood - Lukas Langenegger - Hemotune If you want to know more about Xsensio, we invite you to consult their website and follow their activities on LinkedIn or Twitter. As mentioned by Esmeralda in the episode, have a read at this paper from Nature Biotechnology if you want to know more about the field of biosensing. You can get in touch with Esmeralda through LinkedIn or by email: [email protected] If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: [email protected] And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! You can follow our activities through our website, over LinkedIn, or on Instagram!

To discover the whole episode type “#11 - Turning the lab into a wearable platform - Esmeralda Megally - Xsensio" on your streaming platform.

Most of us have already heard about blockchain technology, as well as many things about cryptocurrencies and how they are transforming traditional approaches in the field of finance. But what about its relevance to healthcare and the potential applications it may have in this space? Eberhard Scheuer is the President of the dHealth Foundation, a not-for-profit organization from Switzerland providing the infrastructure and tools to major stakeholders in healthcare to leverage blockchain technology. He takes us through the basic concepts around blockchain and guides us through the benefits and the applications it may have in this field, when it comes for instance to empowering patients in managing their own health and the data that accompanies it, creating transparency across the pharmaceutical supply chain, or even preserving the authenticity of medical test results! A fascinating exchange and good entry point for newcomers in the field of blockchain and web3 applied to healthcare! Timeline: 02:21 - Eberhard’s background and his entry point in web3 concepts applied to healthcare 06:29 - What blockchain is about 11:12 - Applications of blockchain technology to healthcare and its benefits 21:51 - The example of Estonia with blockchain-enabled electronic health records and the efforts of big tech companies in that regard 25:58 - The reason behind the dHealth Foundation and monetizing health data 38:30 - The services provided by the dHealth Foundation to its partners 46:44 - Misleading ideas around blockchain applications in healthcare What we also talked about with Eberhard Bitcoin Ethereum The Swiss Tropical and Public Health Institute Roche Digital twin Alex Cahana If you want to know more about the dHealth Foundation, we invite you to consult their website and follow their activities on LinkedIn, Medium and Twitter. As mentioned by Eberhard in the episode, if you want to know more about the field of blockchain and the latest trends in that regard, have a look at Blockchain Revolution, Bloomberg Crypto, CoinDesk and Cointelegraph. You can get in touch with Eberhard through LinkedIn or by email: [email protected] If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: [email protected] And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! You can follow our activities through our website, over LinkedIn, or on Instagram!

To discover the whole episode type “#10 - Applying blockchain technology to the healthcare sector - Eberhard Scheuer - dHealth Foundation" on your streaming platform.

Raimundo Sierra is the Founder and CEO from VirtaMed, a Swiss company specialized in surgical simulation systems, covering interventions in orthopaedics, gynecology, laparoscopy and urology, providing true-to-life training for aspiring surgeons and established ones, as part of their continuing education. At the edge of robotics and gaming, Raimundo takes us through the origins of this extremely ambitious project, explaining how the first systems from VirtaMed where developed, and how they currently fit in the diverse surgical curricula provided by established institutions in Europe, China and the US. Beyond the volume of training that such platforms can offer and the positive repercussions in terms of operative results, they also provide equitable access to surgical training, a point that is particularly close to Raimundo's heart given his personal experience. Timeline: 01:36 - Raimundo’s background and what led him to the world of surgical simulation systems 07:33 - The origins of VirtaMed and what differentiates its solutions from medical devices 11:24 - How surgical simulation systems are integrated to medical curricula 16:16 - The components of VirtaMed surgical simulation systems 20:38 - VirtaMed’s global footprint and driving adoption of its products 24:58 - The potential of emerging technologies like machine learning in the field of surgical simulation 27:11 - How VirtaMed works with surgeons 34:47 - VirtaMed’s business model What we also talked about with Raimundo: Stefan Tuchschmid AANA AGA Charité - Universitätsmedizin Berlin B. Braun Melsungen AG Bruno Schmied Dieter Hahnloser Melanie Aregger Avelo We cited with Raimundo some of the past episodes from the series: #2 - Treating liver cancer with surgical robotics - Lucien Blondel - Quantum Surgical #7 - Redefining motor rehabilitation with digital neurotherapeutics - Naveed Ejaz - Mindmaze If you want to know more about VirtaMed, we invite you to consult their website and follow their activities on LinkedIn. As mentioned by Raimundo in the episode, you can learn more about the field of surgical simulations and the latest trends in that regard through the following sources: Society for Simulation in Healthcare The PROFICIENCY project You can get in touch with Raimundo by email: [email protected] If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: [email protected] And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! You can follow our activities through our website, over LinkedIn, or on Instagram!

To discover the whole episode type “#9 - Creating the Gran Turismo of surgery - Raimundo Sierra - VirtaMed" on your streaming platform.

Disclaimer: Nikolce and I both work for Roche, nevertheless all opinions expressed in this episode are our own and do not necessarily represent the position of our employer. Nikolce is leading the Organoid Engineering Group at the Roche Institute for Translational Bioengineering. Organoids are miniaturised versions of the organs and tissues that make up our bodies, sharing phenotypic and genetic aspects of them. They carry a lot of hope in terms of applications in healthcare, from the replacement of animal testing involved in the assessment of drug safety and efficacy, to personalized medicine where they can be leveraged to inform the treatment most suitable to a particular patient, or in terms of potential transplants to address certain diseases. We exchanged with Nikolce on the what, the how and the why behind this fascinating field of bioengineering, which tremendously developed over the past years. He takes us through the current status of the technology and the clinical applications it has already demonstrated, and shares his view on how the field will evolve in the future. Timeline: 03:13 - Mandate and ambition of the Roche Institute for Translational Bioengineering 06:18 - What organoids are and from which tissues they are derived 09:53 - Reprogramming cells’ fates from tissues and deriving induced pluripotent stem cells 11:05 - Growing organoids in vitro and related challenges 13:50 - Applications leveraged at the ITB and the types of tissues at stake 15:55 - Refining the biology and turning the theoretical promises around organoids into practice 20:38 - Towards the use of organoids as human grafts or replacing animal testing 22:37 - Organ-on-a-chip technologies and how they complement organoids 26:17 - Synergies with bioprinting technologies and the challenges that come along with building tissue replicas 28:03 - Looking back at the main advancements since the first organoids came out and their ability to recapitulate features proper to a patient 33:56 - The ethical framework around the use of organoids 37:38 - Moving from Academia to the Industry as a scientist What we also talked about with Nikolce: Matthias Lütolf Hans Clevers Mina Bissell Celeste M. Nelson Nathalie Brandenberg Silke Hoehnel Sun Bioscience Cellink Embryonic stem cells HeLa cells If you want to learn more about the Roche Institute for Translational Bioengineering, we encourage you to consult their website. As mentioned by Nikolce during the episode, the Harvard Stem Cell Institute and Stem Cell Technologies are two information sources worth checking out in case you want to take a deep-dive into what organoids are, and go further into the topics we discussed with him. If you want to reach out to Nikolce, you can contact him over LinkedIn. If you liked the episode, please share it, rate it and leave a 5 star review on Apple Podcasts! You can find more about the podcast through its dedicated website or follow our activities on LinkedIn and Instagram. If you want to give me feedback on this episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: [email protected]

Disclaimer: Nikolce and I both work for Roche, nevertheless all opinions expressed in this episode are our own and do not necessarily represent the position of our employer. To discover the whole episode type “#8 - Using organoids to transform drug discovery - Nikolce Gjorevski - Roche” on your streaming platform.